Skip to contentpdufa.bio

TRYNGOLZA (olezarsen): FDA NDA 218614

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

NDA 218614 is the FDA application for TRYNGOLZA (olezarsen). The FDA's Orange Book lists the applicant of record as IONIS PHARMACEUTICALS INC and the first approval on it as Dec 19, 2024. Code name used in development: IONIS-APOCIII-LRx. Owner today: Ionis Pharmaceuticals, Inc. (Nasdaq: IONS).

Page updated Nov 19, 2026. FDA records: Drugs@FDA NDA 218614 · Orange Book NDA 218614

Names for this drug

Brand name (FDA)TRYNGOLZA
Orange Book trade name: TRYNGOLZA
Active ingredient (FDA)OLEZARSEN SODIUM
Code nameIONIS-APOCIII-LRx
Source: Ionis Pharmaceuticals press release, Nov 3, 2021
“Initiated the Phase 3 CORE study of olezarsen (IONIS-APOCIII-LRx) in patients with severe hypertriglyceridemia (sHTG)”

Who holds the application

FDA applicant of recordIONIS PHARMACEUTICALS INC
FDA Orange Book data files as of Nov 13, 2026
Owner todayIonis Pharmaceuticals, Inc. (IONS)
Source: Ionis Pharmaceuticals press release, Dec 19, 2024
“Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved”

Products on NDA 218614 (FDA Orange Book)

No.Trade nameForm; routeStrengthApproved
001TRYNGOLZA (AUTOINJECTOR)SOLUTION;SUBCUTANEOUSEQ 80MG BASE/0.8ML (EQ 80MG BASE/0.8ML)Dec 19, 2024
002TRYNGOLZA (AUTOINJECTOR)SOLUTION;SUBCUTANEOUSEQ 50MG BASE/0.8ML (EQ 50MG BASE/0.8ML)Jun 24, 2026

FDA decisions we track for this drug

Olezarsen - (CORE)IONS · Decided

Drug page: /drug/olezarsen

Orange Book data: FDA Orange Book data files, as of Nov 13, 2026. Approval dates are the FDA's dates for each product; a later supplement (a new use) does not change them.